Generic Name and Formulations:
Phenytoin sodium, ext-rel 200mg, 300mg; caps.
Indications for PHENYTEK:
Tonic-clonic, psychomotor and neurosurgically induced seizures.
Initially: 100mg 3 times daily. Increase weekly if needed; max 200mg 3 times daily. Once-a-day dosing only with 300mg caps for patients controlled on 300mg daily.
Initially 5mg/kg per day in 2–3 equally divided doses. Increase weekly if needed. Usual maintenance: 4–8mg/kg per day; max 300mg daily.
Diabetes. Impaired liver function. Change dose gradually. Discontinue if rash develops. Monitor serum levels. Use proper dental hygiene. Hormonal contraception. Porphyria. Elderly. Debilitated. Pregnancy. Nursing mothers: not recommended.
Potentiated by acute alcohol ingestion, amiodarone, benzodiazepines (eg, diazepam), chloramphenicol, dicumarol, disulfiram, estrogens, halothane, H2 blockers, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinamides (eg, ethosuximide), sulfonamides, tolbutamide, trazodone, others. Antagonized by chronic alcohol ingestion, carbamazepine, reserpine, others. Antagonizes tricyclic antidepressants, oral anticoagulants, oral contraceptives, estrogens, corticosteroids, doxycycline, digitoxin, furosemide, theophylline, rifampin, quinidine, vitamins D and K, others. Variable effects with phenobarbital, valproic acid, divalproex, others. Absorption decreased by calcium, antacids.
Nystagmus, ataxia, slurred speech, decreased coordination, dizziness, GI disturbances, gingival hyperplasia, osteomalacia, blood dyscrasias, lymphadenopathy, hepatic disease, rash, hyperglycemia, SLE, hypertrichosis.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally